Up And Up Digestive Relief Suspension
NDC Package 11673-706-08
Package Information
Up And Up Digestive Relief (bismuth subsalicylate) suspension is shake well before usefor accurate dosing, use dose cupadults and children 12 years and over:1 dose (30 mL) every 1/2 to 1 hour as needed do not exceed 8 doses (240 mL) in 24 hoursuse until diarrhea stops but not more than 2 dayschildren under 12 years:ask a doctor drink plenty of clear fluids to help prevent dehydration caused by diarrhea. This formulation utilizes a suspension delivery system. Marketed by Target Corporation, this product is identified by NDC 11673-706 and is authorized under FDA application M008.
Identification & Billing
- RxCUI: 308762 - bismuth subsalicylate 525 MG in 30 mL Oral Suspension
- RxCUI: 308762 - bismuth subsalicylate 17.5 MG/ML Oral Suspension
- RxCUI: 308762 - bismuth subsalicylate 1.75 % Oral Suspension
- RxCUI: 308762 - bismuth subsalicylate 262 MG per 15 ML Oral Suspension
- RxCUI: 308762 - bismuth subsalicylate 524 MG per 30 ML Oral Suspension
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 11673 - Target Corporation
- 11673-706 - Up And Up Digestive Relief
- 11673-706-08 - 236 mL in 1 BOTTLE
- 11673-706 - Up And Up Digestive Relief
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 11673-706-08 identifies a specific commercial package of 236 ml in 1 bottle of Up And Up Digestive Relief, a human over the counter drug labeled by Target Corporation. This suspension is formulated for oral use and contains bismuth subsalicylate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Target Corporation on March 15, 2018. The current certification is valid through December 31, 2026.
How is this Target Corporation product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 11673070608. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.